Brisbane, United States
Nitrase Therapeutics, founded in 2018, is a biopharmaceutical innovator based in the United States. Its slogan, "Pioneering Nitrase Biology and Medicines," encapsulates its mission to leverage its unique NITROME platform to harness the potential of nitrases—a novel class of enzymes discovered by the company. These enzymes are pivotal in creating therapies that could alter the progression of diseases such as Parkinson’s and cancer.
The company operates in the Biotechnology, Health Care, and Health and Wellness industries and has earned recognition, including a notable grant from The Michael J. Fox Foundation for Parkinson's Research. As of its last funding round on November 2, 2021, Nitrase Therapeutics secured a $7.00M Series A investment. Investors include prominent names like Sofinnova Partners, Mission Bay Capital, AbbVie Ventures, Alexandria Venture Investments, Dementia Discovery Fund, and Bristol-Myers Squibb.
